| Description | Carboprost tromethamine, a synthetic 15-methyl analogue of prostaglandin F2α, effectively promotes uterine contractions and significantly reduces bleeding during and post-delivery. |
| In vivo | Carboprost tromethamine has been accounted for to be 84-96% successful in the treatment of persistent hemorrhage because of uterine atony. Carboprost tromethamine has a significant effect on the prevention of postpartum hemorrhage in the cesarean section. It has a significant effect on improving the state of hypercoagulable blood and maintaining the stable hemodynamic state [1]. |
| molecular weight | 489.64 |
| Molecular formula | C25H47NO8 |
| CAS | 58551-69-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | H2O: 125 mg/mL (255.29 mM), Sonication is recommended. DMSO: 99 mg/mL(202.19 mM) |
| References | 1. Ling Z, et al. Effect of carboprost tromethamine in prevention of postpartum hemorrhage in cesarean section. Pak J Pharm Sci. 2018 Sep;31(5(Special)):2257-2262. 2. Bai J, et al. A comparison of oxytocin and carboprost tromethamine in the prevention of postpartum hemorrhage in high-risk patients undergoing cesarean delivery. Exp Ther Med. 2014 Jan;7(1):46-50. Epub 2013 Nov 1. |